Piramal Pharma Quarterly Results for Trading Insights
In Mar 2026, Piramal Pharma (PPLPHARMA) reported revenue ₹2,811 Cr and net profit ₹-9 Cr — revenue 0.0% YoY. For annual financials, live price and key ratios, visit PPLPHARMA share price screener.
PPLPHARMA Quarterly Results — Revenue, Profit & EPS Highlights
Piramal Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Browse Piramal Pharma financial data for revenue, profit, balance sheet and cash flow data.
- Revenue of ₹2,811 Cr in Mar 2026 (+32.3% vs Sept 2025, -0.0% vs Mar 2025)
- Net Profit of ₹-9 Cr in Mar 2026 (+90.9% vs Sept 2025, -105.8% vs Mar 2025)
- EBITDA of ₹344 Cr in Mar 2026 (+43.9% vs Sept 2025)
- Operating Margin of 10.0% in Mar 2026 (+2.0pp vs Sept 2025)
- Earnings Per Share of ₹-0.07 in Mar 2026 (+90.7% vs Sept 2025)
Piramal Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
PPLPHARMA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 2,811 | 2,124 | 2,812 | 2,031 | 2,193 | 32.3% | 0.0% |
| Net Profit (₹ Cr) | -9 | -99 | 154 | -82 | -136 | - | - |
| EBITDA (₹ Cr) | 344 | 239 | 619 | 204 | 208 | - | - |
| EPS (₹) | -0.07 | -0.75 | 1.16 | -0.62 | -1.03 | - | - |
| Operating Margin (%) | 10.0% | 8.0% | 20.0% | 6.0% | 7.0% | - | - |
PPLPHARMA Share Price Trend — 1-Year Movement Across Quarterly Results
Piramal Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore Piramal Pharma stock price data download to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
PPLPHARMA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Piramal Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹469,405.89 Cr | 1941.1 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 171.8 |
|
Divis Laboratories
Mar 2026 |
₹194,269.91 Cr | 7248.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 256.0 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹191,454.40 Cr | 4961.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.1 |
|
Zydus Life Science
Mar 2026 |
₹115,616.29 Cr | 1108.7 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 87.6 |
|
Cipla
Mar 2026 |
₹114,318.19 Cr | 1410.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 205.3 |
All amounts in ₹ Crores